Infection risk mitigation with complement inhibitors in kidney disease
Clicks: 7
ID: 314760
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
1.8
/100
7 views
6 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #47 of 109 articles by views in nephrology dialysis transplantation
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Complement inhibitors are increasingly used in kidney diseases, ranging from complement-mediated thrombotic microangiopathies to glomerulonephritis. Because complement is central to host defence against encapsulated bacteria, therapeutic blockade creates a predictable infectious vulnerability requiring structured prevention strategies. This narrative review integrates complement biology with evidence from pivotal kidney trials, pharmacovigilance analyses, and national public health recommendations to propose a pragmatic framework for mitigating infection-risk in patients treated with complement inhibitors. Key complement functions (C3b-mediated opsonisation, C3a/C5a-driven inflammation, and membrane attack complex formation) underlie target-specific patterns of infectious risk. Terminal C5 inhibition (eculizumab, ravulizumab) confers a reproducible exposure-adjusted risk of invasive meningococcal disease, including rare but documented infection-related mortality, with breakthrough infections reported despite vaccination. In contrast, inhibition at the level of C3/C3b or the alternative pathway amplification loop has not, to date, demonstrated a consistent encapsulated-pathogen signal in phase 3 kidney trials, although follow-up remains limited and rare events cannot be excluded. Effective prevention relies on target-adapted vaccination against encapsulated bacteria, consideration of antimicrobial prophylaxis when therapy must begin before vaccine protection is established—and in selected higher-risk settings during sustained complement blockade—and structured patient education with rapid-access pathways for febrile illness. Chronic kidney disease, dialysis exposure, transplantation, and concomitant immunosuppression may further amplify infectious risk and attenuate vaccine responsiveness. Infection risk under complement inhibition is target-dependent and not eliminated by vaccination alone, particularly with terminal C5 blockade. Mechanism-informed, kidney-specific prevention strategies are essential as complement therapies expand into routine clinical practice.
| Reference Key |
openalex_W7162214381
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Mathilde Berghmans, François Seghers, Şafak Mirioğlu, Andreas Kronbichler, Johann Morelle |
| Journal | nephrology dialysis transplantation |
| Year | 2026 |
| DOI |
10.1093/ndt/gfag113
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.